Greenwich LifeSciences, Inc. (GLSI) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Stafford, TX, 美国. 现任CEO为 Snehal S. Patel.
GLSI 拥有 IPO日期为 2020-09-25, 4 名全职员工, 在 NASDAQ Capital Marke, 市值为 $358.97M.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
